David W. Dillon

David W. Dillon is Chief Financial Officer of Verndari, Inc., a biopharmaceutical company based in Napa, California, that aims to transform global health through next-generation vaccine science. As Chief Financial Officer, Mr. Dillon oversees financial, business development, and business services functions at Verndari.

Mr. Dillon is the president and founder of Wesley Capital Holdings, LLC in Pittsburgh, Pennsylvania. Wesley Capital Holdings provides advisory services, valuations, and analysis of investment opportunities. In addition, it provides private companies with assistance on merger and acquisition transactions, joint venture organization and structure, and capital structure issues.

From 1993 to 2008, Mr. Dillon was the co-founder, executive vice president, and chief financial officer of MED3000 Group, Inc., a management and information technology company serving more than 10,500 multi-specialty physicians through 12 operating centers nationwide. During his tenure at MED3000, he also was a member of the executive committee and board of directors. MED3000 grew to more than 1,400 employees with revenues exceeding $150 million and EBITDA in excess of $16 million. MED3000 Group won numerous awards, including being listed in the Pittsburgh Business Times Top 100 fastest growing companies in the Pittsburgh Region for seven years, and being named one of the largest healthcare technology companies by Healthcare Informatics. MED3000 was later sold to McKesson.

Prior to MED3000, Mr. Dillon was an investment banker with Mid-Atlantic Capital Group, Inc., in Pittsburgh. He served as the lead advisor on numerous debt placements, mergers and acquisitions, and valuations for middle-market clients.

Mr. Dillon received a B.S. in Finance and Accounting from the McIntire School of Commerce at the University of Virginia in 1985. He received an M.B.A. with concentrations in strategy and finance from Harvard University in 1990.